Exact Mass: 499.3661

Exact Mass Matches: 499.3661

Found 117 metabolites which its exact mass value is equals to given mass value 499.3661, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine

3-(tetracosa-6,9,12,15,18,21-hexaenoyloxy)-4-(trimethylazaniumyl)butanoate

C31H49NO4 (499.3661)


(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(7Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-7,9,12,15,18,21-hexaenoylcarnitine

3-(tetracosa-7,9,12,15,18,21-hexaenoyloxy)-4-(trimethylazaniumyl)butanoate

C31H49NO4 (499.3661)


(7Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-7,9,12,15,18,21-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (7Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-7,9,12,15,18,21-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-7,9,12,15,18,21-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (7Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-7,9,12,15,18,21-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-[(1R,2R,3R)-3-Hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine

3-({7-[3-hydroxy-2-(3-hydroxyoctyl)-5-oxocyclopentyl]heptanoyl}oxy)-4-(trimethylazaniumyl)butanoate

C27H49NO7 (499.3509)


7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5E)-7-[3,5-Dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine

3-({7-[3,5-dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoyl}oxy)-4-(trimethylazaniumyl)butanoate

C27H49NO7 (499.3509)


(5E)-7-[3,5-dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5E)-7-[3,5-dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E)-7-[3,5-dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5E)-7-[3,5-dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine

3-{[18-(3-ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoyl]oxy}-4-(trimethylazaniumyl)butanoate

C30H45NO5 (499.3298)


(4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10E,12E,16Z)-18-(3-ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   
   

zooxanthellamine

zooxanthellamine

C30H45NO5 (499.3298)


   

Leu Val Val Val Gly

Leu Val Val Val Gly

C24H45N5O6 (499.337)


   

Ile Ile Arg Val

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Ile Ile Val Arg

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Ile Leu Arg Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Ile Leu Val Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Ile Arg Ile Val

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Ile Arg Leu Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Ile Arg Val Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Ile Arg Val Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Ile Val Ile Arg

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylbutanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Ile Val Leu Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylbutanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Ile Val Arg Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Ile Val Arg Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Lys Lys Lys Pro

(2S)-1-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]hexanoyl]pyrrolidine-2-carboxylic acid

C23H45N7O5 (499.3482)


   

Lys Lys Pro Lys

(2S)-6-amino-2-{[(2S)-1-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanoyl]pyrrolidin-2-yl]formamido}hexanoic acid

C23H45N7O5 (499.3482)


   

Lys Pro Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-{[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidin-2-yl]formamido}hexanamido]hexanoic acid

C23H45N7O5 (499.3482)


   

Leu Ile Arg Val

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Leu Ile Val Arg

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Leu Leu Arg Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Leu Leu Val Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Leu Arg Ile Val

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Leu Arg Leu Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Leu Arg Val Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Leu Arg Val Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Leu Val Ile Arg

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylbutanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Leu Val Leu Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylbutanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Leu Val Arg Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Leu Val Arg Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Pro Lys Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-pyrrolidin-2-ylformamido]hexanamido]hexanamido]hexanoic acid

C23H45N7O5 (499.3482)


   

Arg Ile Ile Val

(2S)-2-[(2S,3S)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-methylpentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Arg Ile Leu Val

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-4-methylpentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Arg Ile Val Ile

(2S,3S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-methylbutanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Arg Ile Val Leu

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-methylbutanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Arg Leu Ile Val

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-methylpentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Arg Leu Leu Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-4-methylpentanamido]-3-methylbutanoic acid

C23H45N7O5 (499.3482)


   

Arg Leu Val Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-methylbutanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Arg Leu Val Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-methylbutanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Arg Val Ile Ile

(2S,3S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-methylpentanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Arg Val Ile Leu

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-methylpentanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Arg Val Leu Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-4-methylpentanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Arg Val Leu Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-4-methylpentanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Val Ile Ile Arg

(2S)-2-[(2S,3S)-2-[(2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Val Ile Leu Arg

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Val Ile Arg Ile

(2S,3S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Val Ile Arg Leu

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Val Leu Ile Arg

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methylpentanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Val Leu Leu Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methylpentanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C23H45N7O5 (499.3482)


   

Val Leu Arg Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Val Leu Arg Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Val Arg Ile Ile

(2S,3S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Val Arg Ile Leu

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Val Arg Leu Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-methylpentanoic acid

C23H45N7O5 (499.3482)


   

Val Arg Leu Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-4-methylpentanoic acid

C23H45N7O5 (499.3482)


   

LLLAA

Leu Leu Leu Ala Ala

C24H45N5O6 (499.337)


   

n-Octadecyl-trimethyl-ammonium-3-hydroxy-2-naphthoate

n-Octadecyl-trimethyl-ammonium-3-hydroxy-2-naphthoate

C32H53NO3 (499.4025)


   

Boc-L-Dab(Boc)-OH * DCHA

Boc-L-Dab(Boc)-OH * DCHA

C26H49N3O6 (499.3621)


   

Ethanol, 2,2-(2-heptadecyl-4(5H)-oxazolylidene)bis(methyleneoxy-2,1-ethanediyloxy)bis-

Ethanol, 2,2-(2-heptadecyl-4(5H)-oxazolylidene)bis(methyleneoxy-2,1-ethanediyloxy)bis-

C28H53NO6 (499.3873)


   

di(tetradecanoyloxy)aluminum,hydrate

di(tetradecanoyloxy)aluminum,hydrate

C28H56AlO5 (499.3943)


   

7-[(1R,2R,3R)-3-Hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine

7-[(1R,2R,3R)-3-Hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoylcarnitine

C27H49NO7 (499.3509)


   

(5E)-7-[3,5-Dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine

(5E)-7-[3,5-Dihydroxy-2-(3-hydroxyoctyl)cyclopentyl]hept-5-enoylcarnitine

C27H49NO7 (499.3509)


   

(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine

(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-6,9,12,15,18,21-hexaenoylcarnitine

C31H49NO4 (499.3661)


   

(7Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-7,9,12,15,18,21-hexaenoylcarnitine

(7Z,9Z,12Z,15Z,18Z,21Z)-Tetracosa-7,9,12,15,18,21-hexaenoylcarnitine

C31H49NO4 (499.3661)


   

(4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine

(4Z,7Z,10E,12E,16Z)-18-(3-Ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine

C30H45NO5 (499.3298)


   
   

N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C29H45N3O4 (499.341)


   

N-[(5R,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5R,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C29H45N3O4 (499.341)


   

N-[(5R,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5R,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C29H45N3O4 (499.341)


   

N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C29H45N3O4 (499.341)


   

N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C29H45N3O4 (499.341)


   

N-[(5R,6R,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5R,6R,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C29H45N3O4 (499.341)


   
   
   

(9Z,12Z,15Z,18Z,21Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]tetracosa-9,12,15,18,21-pentaenamide

(9Z,12Z,15Z,18Z,21Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]tetracosa-9,12,15,18,21-pentaenamide

C32H53NO3 (499.4025)


   

(6Z,9Z,12Z,15Z,18Z,21Z)-N-(1,3-dihydroxyoctan-2-yl)tetracosa-6,9,12,15,18,21-hexaenamide

(6Z,9Z,12Z,15Z,18Z,21Z)-N-(1,3-dihydroxyoctan-2-yl)tetracosa-6,9,12,15,18,21-hexaenamide

C32H53NO3 (499.4025)


   

(6Z,9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]octadeca-6,9,12,15-tetraenamide

(6Z,9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]octadeca-6,9,12,15-tetraenamide

C32H53NO3 (499.4025)


   

(7Z,10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]docosa-7,10,13,16,19-pentaenamide

(7Z,10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]docosa-7,10,13,16,19-pentaenamide

C32H53NO3 (499.4025)


   

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxydecan-2-yl)docosa-4,7,10,13,16,19-hexaenamide

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxydecan-2-yl)docosa-4,7,10,13,16,19-hexaenamide

C32H53NO3 (499.4025)


   

(9Z,12Z,15Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]octadeca-9,12,15-trienamide

(9Z,12Z,15Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]octadeca-9,12,15-trienamide

C32H53NO3 (499.4025)


   

(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide

(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide

C32H53NO3 (499.4025)


   

(8Z,11Z,14Z,17Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]icosa-8,11,14,17-tetraenamide

(8Z,11Z,14Z,17Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]icosa-8,11,14,17-tetraenamide

C32H53NO3 (499.4025)


   

(7Z,10Z,13Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]hexadeca-7,10,13-trienamide

(7Z,10Z,13Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]hexadeca-7,10,13-trienamide

C32H53NO3 (499.4025)


   

(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide

C32H53NO3 (499.4025)


   

(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide

C32H53NO3 (499.4025)


   

(4E,8E,12E)-3-hydroxy-2-(undecanoylamino)hexadeca-4,8,12-triene-1-sulfonic acid

(4E,8E,12E)-3-hydroxy-2-(undecanoylamino)hexadeca-4,8,12-triene-1-sulfonic acid

C27H49NO5S (499.3331)


   

(E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid

(E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid

C27H49NO5S (499.3331)


   

(E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxyundec-4-ene-1-sulfonic acid

(E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxyundec-4-ene-1-sulfonic acid

C27H49NO5S (499.3331)


   

(4E,8E,12E)-2-(dodecanoylamino)-3-hydroxypentadeca-4,8,12-triene-1-sulfonic acid

(4E,8E,12E)-2-(dodecanoylamino)-3-hydroxypentadeca-4,8,12-triene-1-sulfonic acid

C27H49NO5S (499.3331)


   

(4E,8E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tetradeca-4,8-diene-1-sulfonic acid

(4E,8E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tetradeca-4,8-diene-1-sulfonic acid

C27H49NO5S (499.3331)


   

(4E,8E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid

(4E,8E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid

C27H49NO5S (499.3331)


   

(4E,8E,12E)-2-(decanoylamino)-3-hydroxyheptadeca-4,8,12-triene-1-sulfonic acid

(4E,8E,12E)-2-(decanoylamino)-3-hydroxyheptadeca-4,8,12-triene-1-sulfonic acid

C27H49NO5S (499.3331)


   

(4E,8E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]trideca-4,8-diene-1-sulfonic acid

(4E,8E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]trideca-4,8-diene-1-sulfonic acid

C27H49NO5S (499.3331)


   

(4E,8E,12E)-3-hydroxy-2-(tridecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid

(4E,8E,12E)-3-hydroxy-2-(tridecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid

C27H49NO5S (499.3331)


   

2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxyundecane-1-sulfonic acid

2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxyundecane-1-sulfonic acid

C27H49NO5S (499.3331)


   

4-[3-butanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

4-[3-butanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C27H49NO7 (499.3509)


   

4-[3-propanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

4-[3-propanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C27H49NO7 (499.3509)


   

4-[3-acetyloxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

4-[3-acetyloxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C27H49NO7 (499.3509)


   

lysoDGTS 18:1

lysoDGTS 18:1

C28H53NO6 (499.3873)


   
   
   

NA-Tyr 22:2(13Z,16Z)

NA-Tyr 22:2(13Z,16Z)

C31H49NO4 (499.3661)


   
   
   
   

Cer 14:2;O2/18:4

Cer 14:2;O2/18:4

C32H53NO3 (499.4025)


   
   

ST 28:4;O3;Gly

ST 28:4;O3;Gly

C30H45NO5 (499.3298)


   

ST 29:3;O2;Gly

ST 29:3;O2;Gly

C31H49NO4 (499.3661)


   
   

2-({1,3-dihydroxy-2-[(1-hydroxyethylidene)amino]butylidene}amino)-n-(1-hydroxy-2-oxopentadecyl)-3-methylbutanimidic acid

2-({1,3-dihydroxy-2-[(1-hydroxyethylidene)amino]butylidene}amino)-n-(1-hydroxy-2-oxopentadecyl)-3-methylbutanimidic acid

C26H49N3O6 (499.3621)


   

(2s)-2-{[(2s,3r)-1,3-dihydroxy-2-[(1-hydroxyethylidene)amino]butylidene]amino}-n-[(1s)-1-hydroxy-2-oxopentadecyl]-3-methylbutanimidic acid

(2s)-2-{[(2s,3r)-1,3-dihydroxy-2-[(1-hydroxyethylidene)amino]butylidene]amino}-n-[(1s)-1-hydroxy-2-oxopentadecyl]-3-methylbutanimidic acid

C26H49N3O6 (499.3621)